Scarica l'app Stockscreener
45.59
0.98%
-0.45
Precedente Chiudi:
$46.04
Aprire:
$45.53
Volume 24 ore:
416.54K
Relative Volume:
0.67
Capitalizzazione di mercato:
$1.36B
Reddito:
$232.39M
Utile/perdita netta:
$-26.79M
Rapporto P/E:
-42.20
EPS:
-1.0804
Flusso di cassa netto:
$4.41M
1 W Prestazione:
-4.80%
1M Prestazione:
-15.37%
6M Prestazione:
-33.67%
1 anno Prestazione:
+40.45%
Intervallo 1D:
$45.16
$46.12
Intervallo di 1 settimana:
$44.73
$47.39
Portata 52W:
$30.27
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
45.59 | 1.36B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-10 | Ripresa | H.C. Wainwright | Buy |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
After an $18.03-per-share option exercise, AnaptysBio (ANAB) director sells 5,000 shares. - Stock Titan
Director Hollings C. Renton plans to sell 5,000 AnaptysBio (ANAB) shares valued at about $249K. - Stock Titan
Latigo Biotherapeutics, Inc. Common Stock (LTGO) Earnings Reports & Dates - FXEmpire
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates - Zacks Investment Research
Spin-off leaves AnaptysBio (ANAB) a lean royalty firm - Stock Titan
AnaptysBio (ANAB) director adds shares as RSUs vest - Stock Titan
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Canada
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage - investing.com
ANAB Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance UK
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - MarketBeat
U.S. Earnings Preview: After Market Close Sept. 8 - moomoo.com
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB - marketbeat.com
ANAB Q2'26 Earnings: revenue estimate is 8.89M USD - TradingView
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
U.S. Earnings Preview: After Market Close Sept. 1 - Moomoo
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com Nigeria
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com India
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Canada
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com South Africa
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? - Investing.com
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com India
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com UK
Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc. - marketbeat.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio Inc. (ANAB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB - MarketBeat
Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes Position in AnaptysBio, Inc. $ANAB - MarketBeat
ANAB Maintained by TD Cowen -- Price Target Lowered to $70 - GuruFocus
TD Cowen lowers Anaptysbio stock price target to $70 on FDA review - Investing.com UK
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating - Moomoo
TD Cowen lowers Anaptysbio stock price target to $70 on FDA review - Investing.com India
AnaptysBio, Inc. (ANAB) Earnings Preview: The First Full Royalty-Model Quarter Matters More Than the Headline EPS - AlphaStreet
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70 - Moomoo
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - MarketBeat
Greenhaven Road Investment Management, L.P.'s AnaptysBio Inc(ANAB) Holding History - GuruFocus
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup - ChartMill
U.S. Earnings Preview: After Market Close Aug. 18 - Moomoo
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control - Yahoo Finance
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HOLLINGS C RENTON | Director |
Oct 01 '26 |
Proposed Sale |
49.87 |
5,000 |
249,372 |
0 |
| RENTON HOLLINGS | Director |
Oct 01 '26 |
Sale |
49.87 |
5,000 |
249,372 |
10,995 |
| Orwin John A | Director |
Sep 15 '26 |
Option Exercise |
0.00 |
1,300 |
0 |
17,995 |
| JOE ANTHONY WARE | Director |
Jul 13 '26 |
Proposed Sale |
67.17 |
10,694 |
718,333 |
0 |
| JOE ANTHONY WARE | Director |
Jun 30 '26 |
Proposed Sale |
67.79 |
6,030 |
408,774 |
0 |
| DENNIS MULROY | Officer |
Jun 29 '26 |
Proposed Sale |
63.45 |
9,476 |
601,213 |
0 |
| DENNIS MULROY | Officer |
Jun 26 '26 |
Proposed Sale |
60.82 |
10,000 |
608,183 |
0 |
| DENNIS MULROY | Officer |
Jun 17 '26 |
Proposed Sale |
60.00 |
850 |
51,000 |
0 |
| DENNIS MULROY | Officer |
Jun 16 '26 |
Proposed Sale |
60.00 |
1,265 |
75,900 |
0 |
| DENNIS MULROY | Officer |
Jun 15 '26 |
Proposed Sale |
57.65 |
20,000 |
1,153,014 |
0 |
3.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):